ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Prana Biotechnology Ltd ADS

Prana Biotechnology Ltd ADS (PRAN)

2.0597
0.00
(0.00%)
At close: November 05 4:00PM
2.0597
0.00
( 0.00% )

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
2.0597
Bid
1.98
Ask
2.10
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
2.0597
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

PRAN Latest News

Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy

Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) (“Prana” or “the Company”) has today announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation for its lead...

Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in Prana

Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in Prana PR Newswire MELBOURNE, Australia and SAN FRANCISCO, Jan. 2, 2019 MELBOURNE, Australia and SAN...

Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA

PBT434 prevents alpha-synuclein aggregation, preserves neurons, reduces glial cell inclusions and slows motor dysfunction in an animal model of Multiple System Atrophy Prana Biotechnology...

PBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement Disorders

Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) has today announced it will be presenting further pre-clinical...

First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases

Highlights: Prana enrols and doses its first cohort of healthy volunteers in its Phase I clinical trial Evidence supports activity of PBT434 to prevent α-synuclein accumulation...

Prana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian Diseases

Highlights: Prana receives ethics committee approval for a clinical trial evaluating first in human dosing of PBT434 Recruitment has commenced for the first cohort of healthy...

Prana Commences Research Collaboration with Takeda for the Treatment of Parkinson's Disease Gastrointestinal Neuropathology

PBT434, Prana’s lead drug in preclinical development for movement disorders, to be profiled in collaborative venture Prana Biotechnology Ltd (ASX:PBT)(NASDAQ:PRAN) today announced a...

Prana's PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration

Scientific Journal Acta Neuropathologica publishes pre-clinical data Prana Biotechnology Ltd (NASDAQ: PRAN) (ASX: PBT) today announced the article “The novel compound PBT434 prevents...

Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development

David Stamler, M.D., has joined Prana Biotechnology (ASX: PBT) (NASDAQ: PRAN) as Chief Medical Officer and Senior Vice President, Clinical Development, based in San Francisco. Prior to...

New Data from Reach2HD Trial Presented at American Neurological Association Annual Meeting

Prana Biotechnology Ltd (ASX:PBT/NASDAQ:PRAN) is pleased to announce that further analysis of the cognitive results of its Reach2HD trial to treat Huntington Disease was presented in a...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ARBBARB IOT Group Ltd
$ 1.22
(116.12%)
7.74M
QLYSQualys Inc
$ 152.50
(18.93%)
100.68k
TMCITreace Medical Concepts Inc
$ 6.60
(14.58%)
35.14k
REBNReborn Coffee Inc
$ 1.964
(14.19%)
3.23k
PRQRProQR Therapeutics NV
$ 4.0455
(13.00%)
200
EXASEXACT Sciences Corporation
$ 51.44
(-28.07%)
1.46M
SMCXDefiance Daily Target 2X Long SMCI ETF
$ 1.8301
(-23.75%)
3.18M
AVNWAviat Networks Inc
$ 17.14
(-18.11%)
18.83k
LDTCLeddarTech Holdings Inc
$ 0.2211
(-14.93%)
5.3k
SMCISuper Micro Computer Inc
$ 24.43
(-11.81%)
16.53M
SMCISuper Micro Computer Inc
$ 24.43
(-11.81%)
16.53M
ARBBARB IOT Group Ltd
$ 1.22
(116.12%)
7.74M
ELABElevai Labs Inc
$ 0.0212
(-0.93%)
7.73M
DJTTrump Media and Technology Group Corporation
$ 33.51
(-1.27%)
4.87M
LILMLilium NV
$ 0.0583
(12.12%)
4.23M

PRAN Discussion

View Posts
 HonTer HonTer 6 years ago
What's going on?
👍️0
yankees18 yankees18 6 years ago
come on u can squeeze, milly float
👍️0
crudeoil24 crudeoil24 6 years ago
Life Sciences out of Boston invested $32M earlier this month in Prana. The OS here is less than 10M. Prana is based in Australia.
👍️0
TheFinalCD TheFinalCD 6 years ago
PRAN NEWS http://pranabio.com/news/prana-receives-orphan-designation-for-pbt434-for-treatment-of-msa
👍️0
crudeoil24 crudeoil24 6 years ago
Conducting phase I > plus good news today from FDA.
👍️0
yankees18 yankees18 6 years ago
took some
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 6 years ago
PRAN 1.90 33% up
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 6 years ago
PRAN 1.42 in PM FDA NEWS Prana receives first orphan drug designation from the FDA for the treatment of Multiple System Atrophy



MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 31st January 2019: Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) (“Prana” or “the Company”) has today announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation for its lead molecule, PBT434, for the treatment of Multiple System Atrophy (MSA). This is the first time the FDA has granted orphan designation to a drug for the treatment of MSA.



Orphan Drug designation by the FDA entitles Prana to seven years of market exclusivity for the use of PBT434 in the treatment of MSA and qualifies the sponsor of the drug for various development incentives of the Orphan Drug Act, including tax credits for qualified clinical testing.



Prana’s successful application was based on the proposed use of PBT434 as a treatment for MSA, including the medical and scientific rationale. The application articulated how PBT434 prevents a-synuclein accumulation, preserves neurons, and improves motor function in a widely accepted animal model of MSA. Alpha-synuclein is of great interest because aggregated forms of the protein are a pathological hallmark of Parkinsonian conditions, including MSA, and it represents a recognised therapeutic target by the scientific community.



“We are pleased that the FDA has acknowledged the importance of PBT434 as a potential treatment for MSA. This recognition, in conjunction with the recent investment from Life Biosciences, positions us strongly to accelerate the development of PBT434 for this devastating condition,” said Dr David Stamler, Chief Medical Officer.



Prana has identified a clear unmet medical need with no approved treatments specifically for MSA. Prana is conducting a Phase 1 clinical trial of PBT434 and expects it to be completed this year.



ENDS



Contacts:

Media

Scott Newstead

E: snewstead@we-buchan.com

Tp: +61 429 703 014



Investor Relations

Rebecca Wilson

E: rwilson@we-buchan.com

Tp: +61 0417 382 391

👍️0
ClayTrader ClayTrader 6 years ago
* * $PRAN Video Chart 01-02-19 * *

Link to Video - click here to watch the technical chart video

👍️0
TheFinalCD TheFinalCD 6 years ago
PRAN 2.36 on news , hit 3.29 earlier

👍️0
rivervalley rivervalley 6 years ago
Last wk was a good one for PRAN after a long time with hardly any vol. Hope it keeps going.
👍️0
ClayTrader ClayTrader 6 years ago
* * $PRAN Video Chart 07-05-18 * *

Link to Video - click here to watch the technical chart video

👍️0
rivervalley rivervalley 6 years ago
Bought back in this recently just over $2 so liking this afternoon pop and hope it continues to move back up.
👍️0
Stock player Stock player 7 years ago
No news...stock up good today....what’s in store for tomorrow?
👍️0
@LiftedCapital @LiftedCapital 7 years ago
Monster VOLUME
👍️0
stocktrademan stocktrademan 7 years ago
PRAN buy 2.74

double bottom
pennant breakout soon
http://stockcharts.com/school/doku.php?id=chart_school:chart_analysis:chart_patterns:flag_pennant_continuation









normal chart




log chart



👍️0
ClayTrader ClayTrader 7 years ago
* * $PRAN Video Chart 07-03-17 * *

Link to Video - click here to watch the technical chart video

👍️0
PositiveThoughts PositiveThoughts 7 years ago
Some stocks make no sense to me...in fact, the stock market makes no sense to me. PRAN is a company with a $13.83 Book Value, it has 5 products in the pipeline. It's PBT2 is in Phase 2b trial as a treatment for Alzheimer’s and Huntington’s disease. One product to treat two different diseases. Yet the stock trades in the $2 range. Incredible!
👍️0
Obelax Obelax 8 years ago
Today runner??
👍️0
PLelek PLelek 8 years ago
Ideal short. Any pop is being added to my short position.
👍️0
ClayTrader ClayTrader 8 years ago
* * $PRAN Video Chart 03-30-17 * *

Link to Video - click here to watch the technical chart video
👍️0
Tdash Tdash 8 years ago
???????????hmm
👍️0
Awl416 Awl416 8 years ago
Bingo!
👍️0
ClayTrader ClayTrader 8 years ago
* * $PRAN Video Chart 01-05-17 * *

Link to Video - click here to watch the technical chart video
👍️0
harry crumb harry crumb 8 years ago
great day here with this. $$$
👍️0
oxfordblk oxfordblk 8 years ago
That is another worthless pump. Please provide evidence of what you hope for, then you might be believed.
👍️0
biotechnician biotechnician 8 years ago
More news coming soon $10+ imo. Do your DD.

👍️0
oxfordblk oxfordblk 8 years ago
Look at the website

Prana Alzheimer's disease data features at world leading conference
July 27, 2016

The volume spike didn't occur until yesterday, Aug. 8.
👍️0
jjp2516 jjp2516 8 years ago
Where was this pumped. I have been searching the web for news because of this run and can find anything. Thx
👍️0
oxfordblk oxfordblk 8 years ago
Look again. The dump part of pump/dump is occurring, as always. Maybe a few are recovering losses.
👍️0
ClearlyStocks ClearlyStocks 8 years ago
That right be amazing.
👍️0
biotechnician biotechnician 8 years ago
The Leader in Alzheimer and Huntington Diseases with a tint float, I see $40+
👍️0
jjp2516 jjp2516 8 years ago
Loving it. Must be some news out there somebody knows. Sweeeet.
👍️0
ClearlyStocks ClearlyStocks 8 years ago
$6.69
👍️0
jjp2516 jjp2516 8 years ago
Short squeeze? That peak didnt last long. Still a nice run so far
👍️0
ClearlyStocks ClearlyStocks 8 years ago
$6.40 wow
👍️0
ClearlyStocks ClearlyStocks 8 years ago
Those 5s went weee
👍️0
ClearlyStocks ClearlyStocks 8 years ago
Wowzers. Flying
👍️0
DRBugg DRBugg 9 years ago
http://www.thevistavoice.org/2016/04/19/zacks-prana-biotechnology-limited-nasdaqpran-receives-consensus-rating-of-hold-from-analysts/1074834/
👍️0
DRBugg DRBugg 9 years ago
http://stks.co/e2qR4
👍️0
bobmenji bobmenji 9 years ago
Looks like the YMB fix is complete!
👍️0
bobmenji bobmenji 9 years ago
Notice of AGM out on ASX
👍️0
novicetrader novicetrader 9 years ago
Kadaicher..great to see you back here in Ihub.I remember how useful the discussion between you & Dew on PRAN had been(early 2014 on the Biotechs board)when I used to follow this company.Are you still hopeful for good things here,and if yes, would you care to give any timeline that you see evolving now?For HD/AD, or the Hold to be lifted? Or anything you care to provide, will be appreciated.
Thanks.
👍️0
oxfordblk oxfordblk 9 years ago
Number 1 on the AGM agenda could be the nasdaq noncompliance issue.
👍️0
interestingtome interestingtome 9 years ago
Someone posted on another board that the company said the announcement regarding the annual meeting will come out on Monday (Sunday night EST). Perhaps some other news will come out around the meeting.
👍️0
tbtbtb tbtbtb 9 years ago
Yeah, it's been quiet here. Don't know why.

It's always tricky with PRAN, because you never know when things will change dramatically. But that's what makes it fun too. It sure was fun back when it soared all the way to 13 in a matter of days. Exhilarating! And then, not so exhilarating on the way down. You always wonder if Murphy's Law will hold whenever you sell or reclassify in your case, but ...

Anyway, you mentioned taxes. Does anyone have any thoughts about PRAN ADR's being classified as a FPIC at this time? The tax implications? I probably won't sell any of my shares until the company is generating revenue from PBT2 (hopefully), and thus no longer a PFIC, but I'm a little fuzzy on the implications there.
👍️0
Kadaicher1 Kadaicher1 9 years ago
Hi RKF, the trial has identified plaque reduction. A statement they made on page 3 of the report was interesting, indicating no changes in measurements between 1yr and 2 yr.
http://pranabio.com/wp-content/uploads/2015/08/150826_Prana-Annual-Report-and-4E.pdf
That would be brilliant if the patients were more advanced, but the differences over one year in these earlier stage patients would possibly have been tiny. I would take from that data that PBT2 may have stopped or slowed AD in the second year but the trial is too small to be able to reach that conclusion. Still, no changes over one year is a good sign.
When Prana started the Reach2HD and IMAGINE trials it was always the plan that Reach2HD would lead PBT2 to market and IMAGINE was run to try to attract a pharma partner for the AD program with a demonstration of target engagement.
They are still on track with HD for phase3, and like you I don't think they will have a problem getting the partial hold lifted when the safety analysis and HD trial design are complete.
👍️0
Learning53 Learning53 9 years ago
Whoa this board is strangely quiet...Hmmm. Either no one has anything to say or
*Everyone has left for another board or
*The miscreants have somehow discovered how to pervert this board as well.

I hope it's just that everyone is messaged out and all is well. Anyway, it's good to see so many familiar names here.

Have a good weekend

PS I just "recharacterized" my pran holdings out of a Roth (tax situations based on losses on initial investment) so I'm hoping that great things don't happen for 31 days....then I hope Prana kicks very serious butt. Sorry, being a little bit selfish.

About 30 days from now I will pursue some ideas that might help get things moving - but for now in a holding mode. Still have plenty of shares but can't put them back in a Roth until next month.

It's a strategy that some of you might be interested in as well.
👍️0
interestingtome interestingtome 9 years ago
I noticed you deleted my post asking others to become moderators here. Am I not allowed to communciate about that?
👍️0
Rkf302 Rkf302 9 years ago
Hello all. I am actually glad The yahoo spam board is gone. I would love to hear any thoughts on the absence of any more results or data from Imagine. My guess is that it can only be negative. I would never ask that question on the other board. In the meantime I am ecstatic it worked in Tanzi lab. I believe we will get the FDA hold lifted as soon as Pran submits data.
👍️0